Stem Cell Data Boosts Asterias In Untapped Spinal Injury Space
Motor function in severe spinal injury patients continues to improve six to nine months after administration of Asterias Biotherapeutics’ stem cell treatment in the Phase I/IIa SCiStar study. The company is figuring out its next steps, including in Japan where the path to market is clearer.
You may also be interested in...
StemCells Inc. plunged 81.2% to $0.57 per share on May 31 after the company revealed little chance of success for a Phase II spinal cord injury study, which has been terminated, and said that it may not be able to return any cash to shareholders after StemCells winds down its operations this year.
While its NDA languishes at the US Food and Drug Administration, the EMA’s CHMP has said yes to dostarlimab’s marketing in the EU for endometrial cancer.
After a baptism of fire during the coronavirus pandemic, mRNA vaccine technology has earned its stripes. In less than a year, mRNA vaccines have been catapulted from interesting pipeline prospects to game-changers in the fight against COVID-19. But what does this success mean for the future of the technology?